What methods are recommended to assess a woman's risk of Abdominal Aortic Aneurysm (AAA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Assessing a Woman's Risk of AAA

Women's AAA risk should be assessed through identification of specific risk factors—particularly age ≥65 years, smoking history (current or former), and cardiovascular disease—as these factors substantially elevate AAA prevalence from the baseline 0.7% to as high as 6.4% in high-risk subgroups. 1, 2

Risk Stratification Framework

Primary Risk Factors

The most critical risk factors that identify women at elevated AAA risk include:

  • Smoking history: Current or former smoking increases AAA risk 3.3-fold (OR = 3.29,95% CI 1.86-5.80), making it the single most important modifiable risk factor in women 2
  • Age ≥65 years: Advanced age increases risk 4.6-fold (OR = 4.57,95% CI 1.98-10.54), with prevalence rising from 0.43% at age 65 to 1.15% at age 75 3, 2
  • Cardiovascular disease: History of coronary artery disease or other cardiovascular conditions increases risk 3.6-fold (OR = 3.57,95% CI 2.19-5.84) 2

Secondary Risk Factors

Additional factors that contribute to AAA risk assessment include:

  • Family history of aortic aneurysm or cardiovascular disease 1
  • Hypertension 1
  • Hypercholesterolemia 1
  • Peripheral artery disease 1

Cumulative Risk Assessment

Women with multiple atherosclerotic risk factors demonstrate substantially elevated AAA prevalence rates reaching 6.4%, compared to 0.7% in the general female population. 2 This multiplicative effect means that a woman aged ≥65 years who smokes and has cardiovascular disease represents a distinctly high-risk profile warranting consideration for screening.

Baseline Prevalence Context

Understanding baseline prevalence is essential for risk assessment:

  • General female population aged ≥65 years: 0.43-0.7% prevalence 3, 2
  • Women aged 75 years: 1.15% prevalence 3
  • High-risk women (age ≥65 + smoking + cardiovascular disease): Up to 6.4% prevalence 2

For comparison, men aged ≥65 years have 3.9-9.1% prevalence, representing a 5-13 fold higher baseline risk than women 1, 2

Clinical Application Algorithm

Step 1: Identify if the woman is aged ≥65 years 1, 2

Step 2: Assess smoking status (current, former, or never smoker) 1, 2

Step 3: Evaluate for cardiovascular disease history 2

Step 4: Document additional risk factors (family history, hypertension, hypercholesterolemia, peripheral artery disease) 1

Step 5: Stratify risk:

  • Highest risk: Age ≥65 + smoking history + cardiovascular disease (prevalence up to 6.4%) 2
  • Moderate risk: Age ≥65 + smoking history OR cardiovascular disease 2
  • Lower risk: Age ≥65 without smoking or cardiovascular disease 3

Important Caveats

Rupture Risk Considerations

Women face a four-fold higher rupture risk compared to men with similar-sized aneurysms, making risk assessment particularly critical for mortality prevention 4, 5 The case fatality rate from rupture remains 75-90%, with over half of deaths occurring before hospital arrival 1

Screening Limitations

Current evidence shows that even in high-risk women (smokers, ex-smokers, or those with coronary disease), AAA prevalence remains relatively low at 0.29%, with current smokers showing the highest prevalence of 0.83% but paradoxically the lowest screening attendance at 75.2% 5 This creates a practical challenge where those at highest risk are least likely to engage with screening.

Sex-Specific Thresholds

Women require intervention at smaller aortic diameters (≥5.0 cm) compared to men (≥5.5 cm) due to their elevated rupture risk 1, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Surveillance Protocol for Infrarenal Abdominal Aortic Aneurysm

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.